Reference (year) |
Study design (no. of participants) |
Ethnicity (no. of cases) |
Patient demographics |
Clinical findings |
Concomitant and comorbid disorders |
Treatment(s) |
Clinical outcomes |
QOEa |
Dlova et al2 (2013) |
Retrospective cohort (20) |
South African (18F, 1M), Indian (1F) |
Premenopausal, n=14 (74%); postmenopausal, n=5 (26%); mean age, 42.3 y (range, 27–66 y) |
Frontotemporal hairline recession, n=20 (100%); eyebrow loss, n=10 (50%); lonely hair sign, n=14 (70%); prominent follicular ostia, n=5 (25%); loss of limb hair, n=2 (10%); scalp pain, n=1 (5%); perifollicular papules, n=1 (5%); occiput hair loss, n=1 (5%) |
LPP, n=2; traction alopecia, n=17; hypothyroidism, n=2; diabetes, n=1; HIV, n=1 |
HCQ 200 mg twice daily + clobetasol dipropionate (unspecified concentration) + tacrolimus 0.1% + minoxidil 2% |
At 2-y follow-up, 6/20 (30%) had stabilized FFA; 14/20 (70%) had ongoing hair loss |
2 |
Callender et al3 (2016) |
Retrospective cohort (18) |
African American (18F) |
Premenopausal, n=7 (39%); postmenopausal, n=7 (39%); mean age, 52 y (range, 28–85 y); median duration of disease, 2.5 y |
Frontotemporal hairline recession, n=18 (100%); eyebrow loss, n=13 (72%); perifollicular papules, n=2 (11%); loss of follicular ostia, n=18 (100%); perifollicular erythema, n=3 (17); perifollicular hyperpigmentation, n=8 (44%); occiput hair loss, n=3 (17%); vertex scalp hair loss, n=1 (6%); scalp pain, n=4 (22%); flaking, n=3 (17%); loss of eyelashes, n=1 (6%) |
None reported |
Monotherapy (n=5) and combination therapy (n=11) of topical corticosteroids, intralesional corticosteroids, oral antibiotics, antifungal shampoo, and/or HCQ (dosages unspecified); no treatment, n=2 |
Of those treated (n=16): 1/16 (6%) had hair regrowth; 8/16 (50%) had stabilized FFA; 7/16 (44%) had FFA progression; of those untreated (n=2): 1/2 (50%) had FFA progression; 1/2 (50%) was lost to follow-up |
2 |
Donati et al4 (2011) |
Case series (2) |
Black (2F) |
Postmenopausal, n=2 (100%); mean age, 47.5 y (range, 45–50 y) |
Frontotemporal hairline recession, n=2 (100%); eyebrow loss, n=1 (50%); perifollicular papules, n=2 (100%); facial papules, n=2 (100%); loss of facial hair, n=2 (100%); loss of limb hair, n=2 (100%) |
None reported |
Oral prednisone 0.5 mg/kg/d + HCQ 400 mg/d or chloroquine 250 mg/d |
All had improvement of facial skin and hair regrowth after at least 6 mo |
3 |
Uwakwe et al5 (2018) |
Case series (7) |
African American (7F) |
Premenopausal, n=3 (43%); postmenopausal, n=4 (57%); mean age not reported |
Frontotemporal hairline recession, n=7 (100%); eyebrow loss, n=6 (86%); perifollicular papules, n=3 (43%); perifollicular erythema, n=2 (29%) |
LPPigm, n=7; Sjogren syndrome, n=1; psoriasis, n=1; morphea, n=1 |
HCQ 200–400 mg/d + topical/intralesional corticosteroids (unspecified concentration) + dutasteride (5-ARI) 0.5 mg/d |
4/7 (57%) had stabilized FFA, 3/7 (43%) had FFA progression that slowed FFA progression |
3 |
Naz et al6 (2003) |
Case series (4) |
Afro-Caribbean (1F) |
Postmenopausal; age, 43 y |
Frontotemporal hairline recession, loss of follicular ostia |
None reported |
Topical minoxidil 2% twice daily |
No clinical improvement of FFA at 6 mo follow-up |
3 |
Dlova and Goh7 (2015) |
Case report (1) |
African (1M) |
Age, 35 y |
Frontotemporal hairline recession, eyebrow loss, loss of follicular ostia, perifollicular erythema, perifollicular hyperpigmentation |
None reported |
HCQ 200 mg twice daily + clobetasol ointment 0.05% + tacrolimus ointment 0.1% + topical minoxidil 2% |
Slowed FFA progression at 1 y follow-up |
4 |
Huerth and Kindred8 (2020) |
Case report (1) |
African American (1F) |
Postmenopausal; age, 53 y |
Frontotemporal hairline recession, loss of follicular ostia |
None reported |
HCQ 200 mg twice daily + oral minoxidil 5 mg/d + clobetasol ointment 0.05% twice daily + intralesional triamcinolone (10 mg/cc) injections |
No clinical improvement of FFA at 6 mo follow up |
4 |
Furlan et al9 (2016) |
Case report (1) |
Black (1F) |
Postmenopausal; age, 49 y |
Frontotemporal hairline recession, eyebrow loss, lonely hair sign, perifollicular papules |
Sjogren syndrome |
Triamcinolone injections (40 mg/mL, 1:10 dilution) in scalp monthly + oral finasteride (5-ARI) 2 mg/d + oral chloroquine 250 mg/d + topical minoxidil 5% daily |
FFA stabilized |
4 |